Mitochondrial peptide MOTS‐c suppresses systemic and cardiac inflammasome activation in a diabetic rat model
Experimental Physiology · 2026-08 · 111 (8) · 3742-3752
DOI: 10.1113/ep093714 ↗At a glance
Journal article in Experimental Physiology, published online on 2026-06-19. Written by Aimee R Mills and 3 co-authors. Institution: Buchanan Ocular Therapeutics Unit, Department of Ophthalmology, New Zealand National Eye Centre, University of Auckland, Auckland, New Zealand. Major MEDLINE topics: Inflammasomes, Diabetes Mellitus, Experimental, Diabetes Mellitus, Type 2, Mitochondrial Proteins. 40 references. The full text is freely available (open access, CC BY 4.0). Funded by: Heart Foundation of New Zealand Research Fellowship, Emerging Research First Grants, Health Research Council of New Zealand.
Abstract (original language)
Type 2 diabetes mellitus (T2DM) is associated with chronic systemic and cardiac inflammation, contributing to the development of diabetic cardiomyopathy. The mitochondrial‐derived peptide mitochondrial open reading frame of the 12S rRNA type‐C (MOTS‐c) has emerged as a promising regulator of metabolic and inflammatory pathways. In this study, we investigated the effects of MOTS‐c treatment on leucine‐rich repeat and pyrin domain‐containing receptor 3 (NLRP3) inflammasome activity in a high‐fat diet and streptozotocin‐induced T2DM rat model. MOTS‐c treatment significantly reduced fasting blood glucose and circulating C‐reactive protein levels, while selectively modulating plasma inflammatory cytokines, including interleukin (IL)‐10 and IL‐1β. Immunohistochemical analysis revealed reduced levels of NLRP3, apoptosis‐associated speck‐like protein containing a caspase activation and recruitment domain (ASC), and cleaved caspase‐1 in left ventricular tissue following MOTS‐c administration. Correlation analyses linked IL‐18 and IL‐1β with elevated markers, including low‐density lipoprotein and uric acid, suggesting interplay between overall health and inflammasome activity. These results indicate that MOTS‐c modulates both systemic and cardiac inflammation in T2DM, providing a novel therapeutic approach for reducing cardiovascular risk in diabetic patients.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Buchanan Ocular Therapeutics Unit, Department of Ophthalmology, New Zealand National Eye Centre, University of Auckland, Auckland, New Zealand.
- Centre for Brain Research, University of Auckland, Auckland, New Zealand.
- Auckland Bioengineering Institute, University of Auckland, Auckland, New Zealand.
- Department of Engineering Science and Biomedical Engineering, University of Auckland, Auckland, New Zealand.
ORCID profiles: Toan Pham
Funding
- Heart Foundation of New Zealand Research Fellowship
- Emerging Research First Grants
- Health Research Council of New Zealand
- Auckland Medical Research Foundation
Cite
APA
Mills, A. R., de Souza, A., Pham, T., & Mugisho, O. O. (2026). Mitochondrial peptide MOTS‐c suppresses systemic and cardiac inflammasome activation in a diabetic rat model. Experimental Physiology, 111(8), 3742-3752. https://doi.org/10.1113/ep093714
Vancouver
Mills AR, de Souza A, Pham T, Mugisho OO. Mitochondrial peptide MOTS‐c suppresses systemic and cardiac inflammasome activation in a diabetic rat model. Experimental Physiology. 2026;111(8):3742-3752. doi:10.1113/ep093714
BibTeX
@article{Mills2026,
author = {Mills, Aimee R and de Souza, Antonio and Pham, Toan and Mugisho, Odunayo O},
title = {Mitochondrial peptide MOTS‐c suppresses systemic and cardiac inflammasome activation in a diabetic rat model},
journal = {Experimental Physiology},
year = {2026},
volume = {111},
number = {8},
pages = {3742--3752},
doi = {10.1113/ep093714}
}
EUVIMED